DERM Journey Medical Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1867066 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.0%
TTM net income YoY41.1%
TTM EPS YoY48.6%
Revenue 3-yr CAGR-4.5%
Net income 3-yr CAGR—
Margins
Gross margin65.9%
Operating margin-2.9%
Net margin-7.3%
FCF margin—
EBITDA margin—
Returns
ROE-17.6%
ROA-5.4%
ROIC (approx.)-5.2%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets68.9%
Debt / equity0.79x
Current ratio1.48x
Interest coverage-0.55x
Cash quality & payout
Operating cash flow / net income1.67x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $61.86M | $56.13M |
| Cost of revenue | $20.92M | $20.88M |
| Gross profit | $40.93M | $35.26M |
| R&D expense | $480,000 | $9.86M |
| SG&A expense | $44.37M | $40.20M |
| Operating income | -$8.17M | -$13.68M |
| Interest expense | $3.70M | $2.70M |
| Pretax income | -$11.37M | -$14.61M |
| Income tax | $60,000 | $61,000 |
| Net income | -$11.43M | -$14.67M |
| EPS (basic) | -0.47 | -0.72 |
| EPS (diluted) | -0.47 | -0.72 |
| Weighted avg. shares (diluted) | 24.50M | 20.43M |
| Balance sheet | ||
| Cash & equivalents | $24.09M | $20.30M |
| Receivables | $29.78M | $10.23M |
| Inventory | $9.62M | $14.43M |
| Current assets | $66.87M | $48.18M |
| Intangibles | $27.61M | $31.86M |
| Total assets | $94.59M | $80.24M |
| Current liabilities | $37.44M | $35.17M |
| Long-term debt | $25.28M | $24.88M |
| Total debt | $25.28M | $24.88M |
| Total liabilities | $62.74M | $60.17M |
| Shareholders' equity | $31.85M | $20.07M |
| Net debt | $1.19M | $4.57M |
| Cash flow statement | ||
| Operating cash flow | -$12.44M | -$9.13M |
| Capital expenditure | — | $15.00M |
| Free cash flow | — | -$24.13M |
| Investing cash flow | — | -$15.00M |
| Financing cash flow | $16.23M | $16.99M |
| Stock-based compensation | $6.29M | $6.10M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.